期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 81, 期 4, 页码 466-468出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2021-221422
关键词
-
类别
Three monoclonal antibodies targeting interleukin-23 have been approved for psoriasis treatment, with two also approved for psoriatic arthritis. However, they have shown to be ineffective in axial spondyloarthritis and may be due to generic effects rather than specific inflammation.
The three monoclonal antibodies ustekinumab, guselkumab and risankizumab targeting the p 40 or the 19 subunit of interleukin -23 have now been approved for the indication psoriasis and the former two also for psoriatic arthritis (PsA). Ustekinumab and risankizumab have appeared ineffective in randomised controlled trials with patients with axial spondyloarthritis (axSpA), but post-hoc analyses of PsA trials have now suggested that they may improve back pain symptoms potentially induced by axial inflammation based on PsA. Here we argue that, based on the absence of efficacy in axSpA, this is unlikely and more probably due to generic, non-specific effects, which are not adequately covered by the tools developed for the assessment of inflammation in axSpA.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据